Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.
Ludovini
Vienna
V
Gori
Stefania
S
Pistola
Lorenza
L
Della Fazia
Maria Agnese
MA
Piobbico
Danilo
D
Servillo
Giuseppe
G
Flacco
Antonella
A
Scuderi
Cristina
C
Crinò
Lucio
L
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy* / Q000235:genetics* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012074:Remission Induction; D015898:Tomography Scanners, X-Ray Computed; D000093542:Gemcitabine
D003841:Deoxycytidine; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D002945:Cisplatin; D000093542:Gemcitabine